Physician profile
David Mckee
NPI 1962469973
$2,680.94
in general payments reported to CMS, 2019-2025
30 companies · $764 in 2025
The $764 reported for 2025 was more than what 88% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $620 · 2020: $98.59 · 2021: $475 · 2022: $168 · 2023: $312 · 2024: $245 · 2025: $764.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,221 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,221.34 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $467.95 | 2019-2025 | |
| Astellas Pharma US INC | $445.05 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $286.40 | 2019-2025 | |
| Amgen INC. | $154.36 | 2019-2021 | |
| Hologic Sales and Service, LLC | $127.87 | 2019-2025 | Aptima, Myosure Tissue Removal Device, Fluent Fluid Management System |
| Sumitomo Pharma America, INC. | $125.40 | 2024-2025 | Gemtesa, Myfembree |
| Ethicon US, LLC | $124.29 | 2025 | Dermabond Prineo, Surgiflo Hemostatic Matrix, Vistaseal |
| Duchesnay USA Incorporated | $123.30 | 2019 | |
| Aspira Women'S Health INC | $92.07 | 2021 | |
| Mayne Pharma Commercial LLC | $88.52 | 2023-2025 | |
| Exeltis, USA INC. | $82.10 | 2023-2025 | Slynd |
| Sage Therapeutics, LLC | $71.37 | 2025 | Zurzuvae |
| Evofem Biosciences, INC. | $67.89 | 2021-2022 | |
| Coopersurgical, INC. | $52.27 | 2019-2021 | |
| Amag Pharmaceuticals, INC. | $51.18 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $44.55 | 2023-2025 | Accrufer |
| Exact Sciences Corporation | $44.36 | 2023-2024 | Cologuard Collection Kit |
| Organon LLC | $35.38 | 2022-2025 | Nexplanon, Jada System |
| Boston Scientific Corporation | $28.74 | 2019-2020 | |
| Roche Diagnostics Corporation | $20.95 | 2021 | |
| Lundbeck LLC | $20.33 | 2021 | |
| Supernus Pharmaceuticals, INC. | $20.20 | 2025 | Qelbree |
| Bayer Healthcare Pharmaceuticals INC. | $16.24 | 2025 | |
| Minerva Surgical, INC | $16.19 | 2025 | |
| Millicent US INC | $15.86 | 2023 | Intrarosa |
| Becton, Dickinson and Company | $12.72 | 2023 | Bd Onclarity |
| Nalpropion Pharmaceuticals LLC | $11.59 | 2019 | |
| Mylan Pharmaceuticals INC. | $11.56 | 2020 | |
| Merck Sharp & Dohme LLC | $11.20 | 2019 | |
| Novo Nordisk INC | $11.05 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Mckee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.